PAPER Qaisar R, Karim A, Iqbal MS, Alkahtani SA, Ahmad F

Associations of plasma Neurofilament light chain with sarcopenia and physical capacity in patients with Alzheimer's diseases.

Acta Neurol Belg. 2025 Mar 11; Epub 2025 Mar 11 PubMed.

PAPER Xiao Y, Zhang M, Lu N

Fluorescent Fingerprint Identification of Protein Structural Changes and Disease-Specific Amyloid Beta Aggregates Based on a Single-Nanozyme Sensor Array.

Anal Chem. 2025 Mar 11;97(9):4978-4986. Epub 2025 Feb 25 PubMed.

PAPER Pollock JM, Yew CH, Tripathi A

Utilizing Functionalized Dual-Microbead Interfaces for Measurements of Amyloid-beta (1-42) with Femtomolar Sensitivity.

Langmuir. 2025 Mar 11;41(9):5870-5876. Epub 2025 Feb 24 PubMed.

PAPER Liu J, Chen L, Zhang ZL, Wen W, Zhang X, Wu Z, Wang S

Nano-Collision Electrochemistry for Real-Time Monitoring of Amyloid-β Oligomerization and Rapid Screening of Degrading Drugs.

Anal Chem. 2025 Mar 11;97(9):4898-4905. Epub 2025 Feb 24 PubMed.

Robert Mach on A positron emission tomography tracer for the imaging of oxidative stress in the central nervous system.

COMMENT I congratulate the authors for trying to develop an alternative strategy to imaging reactive oxygen and reactive nitrogen species (ROS/RNS) in vivo with PET. Our group developed the radiotracer, [18F]ROStrace, and we have conducted PET imaging studies to

PAPER Gallagher E, Li S, Lee H, Xu H, Lee VMY, Mach RH, McManus MJ

Noninvasive Detection of Oxidative Stress in a Mouse Model of 4R Tauopathy via Positron Emission Tomography with [18F]ROStrace

Int. J. Mol. Sci. 2025 . International Journal of Molecular Sciences

Risvodetinib

THERAPEUTICS Inhibikase Therapeutics, Inc. IkT-148009 Small Molecule alpha-synuclein Other Between February 2021 and January 2023, Inhibikase ran a Phase 1 single- and multiple-ascending-dose trial. The study enrolled 108 participants, and tested nine single doses fro

COYA 302

THERAPEUTICS Coya Therapeutics IL2 plus Abatacept Combination Other Inflammation In October 2021, an investigator-initiated, open-label study of COYA 302 began at the Houston Methodist Research Institute. The study planned to enroll 10 people with ALS, treat them ever

Giulia Albertini

VIB/KU Leuven
Belgium

PAPER Thayer JA, Petersen JD, Huang X, Hawrot J, Ramos DM, Sekine S, Li Y, Ward ME, Narendra DP

Novel reporter of the PINK1-Parkin mitophagy pathway identifies its damage sensor in the import gate.

bioRxiv. 2025 Feb 20; PubMed.

PAPER Sharma V, Unjum Saqib BZ, Aran KR

Leptin as a potential neuroprotective target in Parkinson's Disease: Exploring its role in Neuroinflammation, oxidative Stress, and dopaminergic neurodegeneration.

Neuroscience. 2025 Mar 8; Epub 2025 Mar 8 PubMed.

PAPER Jiang Y, Jin J, Piao Y, Yin Y, Tang L, Guan Q, Gao Y, Feng T, Wang Z

A simple and effective screening strategy for early multiple system atrophy diagnosis and α-Synuclein forms in erythrocytes.

Front Aging Neurosci. 2025;17:1533504. Epub 2025 Feb 21 PubMed.

PAPER Li WW, Fan DY, Sun Q, Wang LK, Huang BQ, Yu ZY, Tian DY, Shen YY, Tan CR, Zeng GH, Zeng F, Fan J, Wang Z, Wang YJ, Wang J

Temporal Changes in Alzheimer's Disease-Related Biomarkers in the CSF of Cognitively Normal Subjects at Different Ages: The Chongqing Ageing and Dementia Study.

Aging Cell. 2025 Mar 9;:e70036. Epub 2025 Mar 9 PubMed.

PAPER Sanchez E, Coughlan GT, Wilkinson T, Ramirez J, Mirza SS, Baril AA, Dilliott AA, Frank A, Lang AE, Hassan A, Pollock BG, Scott CJ, Marras C, Fischer CE, Seitz D, Andriuta D, Dowlatshahi D, Grimes DA, Tang-Wai DF, Sahlas DJ, Rogaeva EA, Finger E, Robinson JF, Tan K, Binns MA, Tartaglia MC, Borrie MJ, Strong MJ, Ozzoude M, Nanayakkara ND, Goncalves RA, Bartha R, Hegele RA, Farhan SM, Black SE, Kumar S, Symons SP, Haddad SM, Pasternak SH, Arnott SR, Rajji TK, Steeves T, Swardfager W, Ashton NJ, Kvartsberg H, Zetterberg H, Munoz DP, Masellis M, ONDRI Investigators

Association of Plasma Biomarkers With Longitudinal Atrophy and Microvascular Burden on MRI Across Neurodegenerative and Cerebrovascular Diseases.

Neurology. 2025 Apr 8;104(7):e213438. Epub 2025 Mar 10 PubMed.

PAPER Gonzalez AI, Edwards LC, Thomas KR, Weigand AJ, Bordyug M, Brenner EK, Urias UA, Bangen KJ

Growth-associated protein 43 is associated with faster functional decline among amyloid-positive individuals with objectively defined subtle cognitive decline and mild cognitive impairment.

Neuropsychology. 2025 Mar;39(3):248-258. PubMed.